Skip to content

the effect of letrozole on endometrial thickness

Investigating the effect of letrozole on endometrial thickness in IVF candidate patients at Yas Hospital infertility clinic

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120104008611N14
Enrollment
100
Registered
2023-07-19
Start date
2023-07-23
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility. Female infertility

Interventions

Intervention 1: Intervention group:Patients receive letrozole 2.5 mg daily for 5 days from the third day of the menstrual cycle. Intervention 2: Control group: People receive daily placebo for 5 days

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Women diagnosed with infertility IVF candidate women

Exclusion criteria

Exclusion criteria: pregnancy Presence of endometrial pathological lesions The person's lack of consent to participate in the study Intolerance of Letrozole in the patient Presence of Letrozole contraindications in patients such as liver diseases

Design outcomes

Primary

MeasureTime frame
Assess endometrial thickness. Timepoint: The second or third day of the menstrual cycle. Method of measurement: sonography.

Secondary

MeasureTime frame
Biochemical pregnancy. Timepoint: Once, 14 days after fetus transfer. Method of measurement: Blood sampling.;Clinical pregnancy. Timepoint: Once, 6 to 8 weeks after embryo transfer. Method of measurement: Observation of pregnancy sac and heart rate on ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamideh Pakniat

Qazvin University of Medical Sciences

pakniat110@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026